Oppenheimer Asset Management’s GSK GSK Stock Holding History

Oppenheimer Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.22M	Sell	58,370 -14,802	-20%	-$802K	0.04%	438
2025 Q4	$3.59M	Sell	73,172 -72,592	-50%	-$3.39M	0.04%	371
2025 Q3	$6.29M	Buy	145,764 +2,004	+1%	+$78.3K	0.07%	301
2025 Q2	$5.52M	Buy	143,760 +3,654	+3%	+$140K	0.06%	320
2025 Q1	$5.43M	Buy	140,106 +23,369	+20%	+$856K	0.07%	299
2024 Q4	$3.95M	Buy	116,737 +4,342	+4%	+$156K	0.05%	369
2024 Q3	$4.59M	Buy	112,395 +6,468	+6%	+$265K	0.06%	342
2024 Q2	$4.08M	Buy	105,927 +10,942	+12%	+$460K	0.05%	354
2024 Q1	$4.07M	Sell	94,985 -14,784	-13%	-$610K	0.06%	318
2023 Q4	$4.07M	Buy	109,769 +7,502	+7%	+$269K	0.06%	338
2023 Q3	$3.71M	Buy	102,267 +6,638	+7%	+$236K	0.06%	341
2023 Q2	$3.41M	Buy	95,629 +18,144	+23%	+$651K	0.05%	377
2023 Q1	$2.76M	Buy	77,485 +18,558	+31%	+$649K	0.04%	411
2022 Q4	$2.07M	Sell	58,927 -1,395	-2%	-$46.5K	0.03%	472
2022 Q3	$1.78M	Sell	60,322 -6,580	-10%	-$249K	0.03%	478
2022 Q2	$3.64M	Sell	66,902 -9,146	-12%	-$505K	0.06%	321
2022 Q1	$4.14M	Buy	76,048 +3,982	+6%	+$216K	0.06%	331
2021 Q4	$3.97M	Buy	72,066 +12,413	+21%	+$646K	0.05%	353
2021 Q3	$2.85M	Sell	59,653 -1,448	-2%	-$72.7K	0.04%	420
2021 Q2	$3.04M	Sell	61,101 -8,303	-12%	-$399K	0.04%	409
2021 Q1	$3.1M	Buy	69,404 +4,984	+8%	+$226K	0.05%	388
2020 Q4	$2.96M	Sell	64,420 -62,481	-49%	-$2.87M	0.05%	377
2020 Q3	$5.97M	Sell	126,901 -4,919	-4%	-$246K	0.12%	201
2020 Q2	$6.72M	Sell	131,820 -10,045	-7%	-$515K	0.14%	174
2020 Q1	$6.72M	Sell	141,865 -14,586	-9%	-$778K	0.17%	149
2019 Q4	$9.19M	Sell	156,451 -1,235	-0.8%	-$68.7K	0.19%	132
2019 Q3	$8.41M	Buy	157,686 +1,020	+0.7%	+$52.5K	0.19%	135
2019 Q2	$7.84M	Sell	156,666 -86	-0.1%	-$4.32K	0.17%	145
2019 Q1	$8.19M	Sell	156,752 -18,534	-11%	-$926K	0.18%	137
2018 Q4	$8.37M	Sell	175,286 -17,082	-9%	-$841K	0.21%	113
2018 Q3	$9.66M	Sell	192,368 -2,146	-1%	-$109K	0.21%	113
2018 Q2	$9.8M	Sell	194,514 -34,069	-15%	-$1.72M	0.24%	103
2018 Q1	$11.2M	Buy	228,583 +22,071	+11%	+$1.03M	0.28%	91
2017 Q4	$10.5M	Hold	206,512	–	–	0.28%	90
2017 Q3	$10.5M	Buy	206,512 +13,634	+7%	+$692K	0.27%	91
2017 Q2	$10.4M	Buy	192,878 +24,189	+14%	+$1.29M	0.29%	84
2017 Q1	$8.89M	Buy	+168,689	New	+$8.56M	0.25%	96

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Oppenheimer Asset Management's GSK Position: Q1 2026 in Review

Oppenheimer Asset Management reduced its GSK (GSK) stake by 20% in Q1 2026, selling an estimated $802K and leaving 58,370 shares worth $3.22M. The position accounts for 0.04% of the portfolio, ranked #438.

Oppenheimer Asset Management first reported a position in GSK in Q1 2017 and has held it in 37 quarters since. The position peaked at $11.2M in Q1 2018. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Oppenheimer Asset Management held 58,370 shares of GSK worth $3.22M as of Q1 2026.
Oppenheimer Asset Management sold 14,802 GSK shares in Q1 2026, an estimated $802K.
GSK made up 0.04% of Oppenheimer Asset Management's portfolio in Q1 2026, its #438 holding.
Oppenheimer Asset Management first reported a position in GSK in Q1 2017 and has held it in 37 quarters since.
Oppenheimer Asset Management's GSK position peaked at $11.2M in Q1 2018.
1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.